Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tobias Derfuss

Showing results (1-10 of 166) with videos related to

Pageof 17
Sort By:
BMC Medicine|October 6, 2012
Personalized medicine in multiple sclerosis: hope or reality?Tobias Derfuss
Expert Review of Neurotherapeutics|March 19, 2016
Disease activity return after natalizumab cessation in multiple sclerosisMaria Rasenack, Tobias Derfuss
Current Opinion in Neurology|April 11, 2012
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?Tobias Derfuss, Edgar Meinl
Therapeutic Advances in Neurological Disorders|March 16, 2019
The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosisMartin Diebold, Tobias Derfuss
JAMA|July 17, 2012
Evaluating the potential benefit of interferon treatment in multiple sclerosisTobias Derfuss, Ludwig Kappos
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 13, 2022
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: CommentaryÖzgür Yaldizli, Tobias Derfuss
Seminars in Hematology|June 18, 2016
Immunological treatment of multiple sclerosisMartin Diebold, Tobias Derfuss
Journal of Neurovirology|December 6, 2011
Control of HSV-1 latency in human trigeminal ganglia--current overviewKathrin Held, Tobias Derfuss
The Lancet. Neurology|October 4, 2017
PML risk and natalizumab: the elephant in the roomTobias Derfuss, Ludwig Kappos
Journal of Neurology, Neurosurgery, and Psychiatry|April 23, 2013
Predicting PML in natalizumab-treated patients: can we do better?Tobias Derfuss, Ludwig Kappos
Pageof 17

Showing results (1-10 of 166) with videos related to

Sort By:
Pageof 17
BMC Medicine|October 6, 2012
Personalized medicine in multiple sclerosis: hope or reality?Tobias Derfuss
Expert Review of Neurotherapeutics|March 19, 2016
Disease activity return after natalizumab cessation in multiple sclerosisMaria Rasenack, Tobias Derfuss
Current Opinion in Neurology|April 11, 2012
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?Tobias Derfuss, Edgar Meinl
Therapeutic Advances in Neurological Disorders|March 16, 2019
The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosisMartin Diebold, Tobias Derfuss
JAMA|July 17, 2012
Evaluating the potential benefit of interferon treatment in multiple sclerosisTobias Derfuss, Ludwig Kappos
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 13, 2022
All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: CommentaryÖzgür Yaldizli, Tobias Derfuss
Seminars in Hematology|June 18, 2016
Immunological treatment of multiple sclerosisMartin Diebold, Tobias Derfuss
Journal of Neurovirology|December 6, 2011
Control of HSV-1 latency in human trigeminal ganglia--current overviewKathrin Held, Tobias Derfuss
The Lancet. Neurology|October 4, 2017
PML risk and natalizumab: the elephant in the roomTobias Derfuss, Ludwig Kappos
Journal of Neurology, Neurosurgery, and Psychiatry|April 23, 2013
Predicting PML in natalizumab-treated patients: can we do better?Tobias Derfuss, Ludwig Kappos
Pageof 17